BeOne Medicines AG - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ONC Nasdaq 2836 beonemedicines.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BeOne Medicines AG

Biotech Leader BeOne Medicines Poised To Hit Early Buy Points - Oct 1st, 2026 10:44 am
BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run - Sep 5th, 2026 5:06 pm
The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal - Sep 4th, 2026 9:09 pm
BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It? - Sep 4th, 2026 12:44 pm
FDA Approval Marks A Turning Point For BeOne Medicines (ONC) - Sep 1st, 2026 11:01 am
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers - Sep 1st, 2026 10:35 am
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference - Sep 1st, 2026 4:00 am
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines - Aug 31st, 2026 1:00 pm
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer - Aug 31st, 2026 4:00 am
Generative "AI" Macro Data Shows U.S. Impacts - Aug 27th, 2026 2:54 pm
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy? - Aug 27th, 2026 10:00 am
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA - Aug 25th, 2026 8:40 am
BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy? - Aug 25th, 2026 7:55 am
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries - Aug 18th, 2026 4:00 am
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies? - Aug 14th, 2026 5:09 pm
BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ... - Aug 12th, 2026 7:04 pm
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration - Aug 10th, 2026 4:00 am
Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook? - Aug 6th, 2026 6:18 pm
BeOne Medicines Q2 Earnings Call Highlights - Aug 5th, 2026 12:04 pm